Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Tremelimumab in Advanced Rare Solid Tumors
NCT02938793Phase 2Terminated
- Sponsor
- Prisma Health
- Start
- Dec 2016
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in solid tumor, sponsored by Prisma Health. Primary endpoints: Antitumor Activity at 24 months and Incidence of Treatment-Emergent and Non Treatment-Emergent Adverse Events at 24 months. Started Dec 2016; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02938793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938793.